1-20 of 4,470 results for subject:Screening
Librarians' tools
- Search time
- 0.272 seconds
- Solr query time
- 0.008 seconds
- Search query
- subject:Screening
- We searched for
- subject_t:Screening OR subject_ses:92923
Type
House
Session
More
Year
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
More
Subject
More
Publisher
To ask the Secretary of State for Transport, what steps he is taking to (a) provide covid-related advice for travellers and (b) regulate pricing for travel-related PCR testing; and if he will make a statement.
To ask the Secretary of State for Transport, what steps he is taking to (a) provide covid-related advice for travellers and (b) regulate pricing for travel-related PCR testing; and if he will make a statement.
The UK removed all mandatory border health measures on 18 March and Gov.uk guidance has been updated. Passengers travelling from the UK should always check the latest FCDO Travel Advice which covers other countries’ entry requirements.
There are no post-arrival tests required for passengers entering the UK but the government’s focus will continue to be on ensuring that there is accuracy and transparency of pricing in the private testing market.
To ask the hon. Member for Broxbourne, representing the House of Commons Commission, how many positive covid-19 cases were recorded on the Parliamentary estate in each month from November 2021 to March 2022.
To ask the hon. Member for Broxbourne, representing the House of Commons Commission, how many positive covid-19 cases were recorded on the Parliamentary estate in each month from November 2021 to March 2022.
Following the change to Government guidance in February 2022 individuals were no longer required to inform their workplace if they tested positive for Covid. The figures below therefore represent the number of positive cases where an individual chose to share their result.
As the original case information has now been deleted in line with our privacy policies, only a summary per week is available.
25 March–1 April: 47
18–24 March: 75
11–17 March: 51
4–10 March: 47
25 February–3 March: 11
18–24 February: 15
11–17 February: 18
The numbers below represent the number of validated case numbers, using data held by the UKHSA and the Parliamentary test and trace team.
4–10 February: 63
28 January–3 February: 61
21–27 January: 89
14–20 January: 68
7–13 January: 69
31 December–6 January: 110
24–30 December: 119
17–23 December: 128
10–16 December: 193
3–9 December: 66
26 November–2 December: 38
19–25 November: 34
12–18 November: 31
5–11 November: 20
29 October–4 November: 28
To ask the Secretary of State for Health and Social Care, what the total cost of the purchase of covid-19 PCR test kits has been to date; and how many of those kits have been purchased.
To ask the Secretary of State for Health and Social Care, what the total cost of the purchase of covid-19 PCR test kits has been to date; and how many of those kits have been purchased.
The UK Health Security Agency (UKHSA) is unable to provide the information requested on the cost of purchasing of COVID-19 polymerase chain reaction (PCR) tests as this information is commercially sensitive.
PCR test kits are comprised of several components which are individually purchased, prior to assembly. Between April 2020 and March 2022, the UKHSA purchased materials which were manufactured to make 154 million test kits.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the affordability of covid-19 testing for people who are visiting relatives in care homes.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the affordability of covid-19 testing for people who are visiting relatives in care homes.
Visitors are no longer asked to test before entering a care home although they are encouraged to take necessary precautions to keep themselves and their loved ones safe, including staying away from the care home if they are symptomatic or test positive for COVID-19. However, free asymptomatic testing is available for visitors providing personal care before entering the care home, up to twice weekly if visiting more than twice. While visitor testing is no longer required, we will continue to ensure that COVID-19 tests are available through the private market for those who wish to purchase them.
To ask the Secretary of State for Health and Social Care, what has the total cost to the public purse of the Government PCR testing programme been to date; and how many PCR tests have been completed.
To ask the Secretary of State for Health and Social Care, what has the total cost to the public purse of the Government PCR testing programme been to date; and how many PCR tests have been completed.
The UK Health Security Agency is unable to provide the information requested on the total cost of the polymerase chain reaction (PCR) testing programme as it is commercially sensitive.
Between April 2020 and March 2022, 147 million PCR tests have been reported as ‘processed’ through laboratories.
To ask the Secretary of State for Health and Social Care, how many and what proportion of people who are clinically vulnerable and eligible for free priority covid-19 PCR tests have received them.
To ask the Secretary of State for Health and Social Care, how many and what proportion of people who are clinically vulnerable and eligible for free priority covid-19 PCR tests have received them.
It has not proved possible to respond to the hon. Member in the time available before Prorogation.
To ask the Secretary of State for Health and Social Care, how many covid-19 lateral flow test kits have been purchased by his Department; and what was the total cost to the public purse of these kits.
To ask the Secretary of State for Health and Social Care, how many covid-19 lateral flow test kits have been purchased by his Department; and what was the total cost to the public purse of these kits.
It has not proved possible to respond to the hon. Member in the time available before Prorogation.
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the prevalence of covid-19 tests available on the market that have not been approved by his Department.
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the prevalence of covid-19 tests available on the market that have not been approved by his Department.
It has not proved possible to respond to the hon. Member in the time available before Prorogation.
To ask Her Majesty's Government how many NHS trusts have point-of-care teams; and how many of these have access to rapid PCR technology.
To ask Her Majesty's Government how many NHS trusts have point-of-care teams; and how many of these have access to rapid PCR technology.
It has not proved possible to respond to this question in the time available before Prorogation. Ministers will correspond directly with the Member.
To ask the Secretary of State for Health and Social Care, what steps his Department plans to take to ensure adequate supplies of covid-19 (a) PCR and (b) lateral flow tests for care homes.
To ask the Secretary of State for Health and Social Care, what steps his Department plans to take to ensure adequate supplies of covid-19 (a) PCR and (b) lateral flow tests for care homes.
It has not proved possible to respond to the hon. Member in the time available before Prorogation.
To ask the Secretary of State for Health and Social Care, if he will hold discussions with representatives of NHS Test and Trace on the use of the results of privately purchased covid-19 antigen tests to ensure that (a) the spread of covid-19 is tracked and (b) people who may...
To ask the Secretary of State for Health and Social Care, if he will hold discussions with representatives of NHS Test and Trace on the use of the results of privately purchased covid-19 antigen tests to ensure that (a) the spread of covid-19 is tracked and (b) people who may...
It has not proved possible to respond to the hon. Member in the time available before Prorogation.
To ask Her Majesty's Government what steps they are taking to create rapid PCR capability in (1) emergency departments, and (2) acute healthcare settings.
To ask Her Majesty's Government what steps they are taking to create rapid PCR capability in (1) emergency departments, and (2) acute healthcare settings.
It has not proved possible to respond to this question in the time available before Prorogation. Ministers will correspond directly with the Member.
To ask the Secretary of State for Health and Social Care, with reference to the decision to end the free provision of covid-19 tests, what modelling his Department has made of the financial costs of procuring covid-19 (a) lateral flow tests and (b) PCR tests for (i) schools, (ii) care...
To ask the Secretary of State for Health and Social Care, with reference to the decision to end the free provision of covid-19 tests, what modelling his Department has made of the financial costs of procuring covid-19 (a) lateral flow tests and (b) PCR tests for (i) schools, (ii) care...
The UK Health Security Agency (UKHSA) has carried out financial cost modelling to determine the estimated testing costs for care homes and National Health Service primary, secondary and tertiary care services. In 2022/23, the estimated total cost for lateral flow device and polymerase chain reaction testing is approximately £830 million. The UKHSA has not carried out specific modelling for school settings in 2022/23.
Free symptomatic testing will continue for patients in hospital, for whom a test is required for clinical management or to support treatment pathways; those who are eligible for COVID-19 treatments as they are at higher risk of getting seriously ill from COVID-19; and individuals who live or work in high-risk closed settings, such as those in the National Health Service, social care, prisons and other places of detention.
The Department will continue to fund some asymptomatic testing in NHS, adult social care and hospice services during periods of higher prevalence, including for staff and patients. Asymptomatic testing of care home and hospice residents will also be provided on admission and during an outbreak. The UKHSA will continue to review such modelling, planning assumptions and related costs within all settings.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support manufacturing of covid-19 lateral flow tests in the UK.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support manufacturing of covid-19 lateral flow tests in the UK.
In October 2020, the Government commissioned work to support the United Kingdom’s diagnostic industry, to secure a supply of lateral flow device antigen tests and increase domestic production capacity. The Make UK programme delivered two clinically evaluated and regulatory approved antigen tests and provided investment in capital equipment and facilities expansion at three manufacturing companies in the UK.
The UK Health Security Agency has procured 125 million tests from UK companies and has contracts in place to procure further supplies. This represents an increase in production capacity of 3,500%. The Make UK programme has also increased capacity and resilience for current and future public health challenges.
To ask the Secretary of State for Health and Social Care, what comparative assessment his Department has made of the impact of the coronavirus test device approvals (CTDA) process on (a) domestically- and (b) foreign-manufactured covid-19 tests which are not subject to the CTDA process.
To ask the Secretary of State for Health and Social Care, what comparative assessment his Department has made of the impact of the coronavirus test device approvals (CTDA) process on (a) domestically- and (b) foreign-manufactured covid-19 tests which are not subject to the CTDA process.
The coronavirus test device approval (CTDA) is required for all molecular and antigen tests to enter the United Kingdom market. Non-antigen and non-molecular detection tests such as antibodies or biomarker-based testing technologies are currently excluded from the scope of validation. However, these will be monitored and revised as necessary, particularly as technologies become more mature and widespread. Regardless of the country of origin, all tests must meet the standards established in the CTDA regulations.
The ‘Validating COVID-19 tests in the private market’ has assessed the impact of CTDA for UK based and international companies and is available at the following link:
Further to the legislation, we have committed to review this policy by the end of 2022.
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of England’s covid-19 testing capacity in the event of (a) a new variant of covid-19 and (b) an upsurge in hospitalisations.
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of England’s covid-19 testing capacity in the event of (a) a new variant of covid-19 and (b) an upsurge in hospitalisations.
The Government has retained the ability to enable a rapid testing response should it be needed, such as in the case of a new variant of concern. This includes a stock of lateral flow device tests and the ability to increase capacity in testing laboratories and delivery channels. The details of these contingency arrangements would be determined by the specific circumstances and the risks posed by a variant. The success of the COVID-19 vaccination and booster programme and the availability of antiviral treatments has ensured there is a lower risk of severe illness or hospitalisation in the general population.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 12 April 2022 to Question 145835 on Coronavirus: Screening, what criteria are used to determine commercial sensitivity; and what his timescale is for publishing the number of lateral flow device tests issued to the...
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 12 April 2022 to Question 145835 on Coronavirus: Screening, what criteria are used to determine commercial sensitivity; and what his timescale is for publishing the number of lateral flow device tests issued to the...
The specific expenditure on lateral flow device (LFD) tests is commercially sensitive as it could prejudice the Department’s future commercial relations with suppliers if this information were to be disclosed. On 14 April 2022, we published data on the number of LFD tests dispatched from September 2020 to February 2022, by use case. This information is available at the following link:
Prior to September 2020 LFD tests were not in use.
To ask the Secretary of State for Health and Social Care, if he will make free covid-19 lateral flow tests available to people visiting those who are vulnerable or who have underlying health conditions in the event that they would otherwise be unable to do so as a result of...
To ask the Secretary of State for Health and Social Care, if he will make free covid-19 lateral flow tests available to people visiting those who are vulnerable or who have underlying health conditions in the event that they would otherwise be unable to do so as a result of...
The success of the vaccination programme and access to antiviral treatments, natural immunity and increased scientific and public understanding on managing risk, the population has much stronger protection against COVID-19.
Those at risk of serious illness from COVID-19 who are eligible for treatments, will continue to receive free lateral flow device (LFD) tests for use should they develop symptoms. Eligible adult social care staff continue to have access to free twice-weekly LFD tests and symptomatic tests. In addition, free testing will be provided for residential special educational needs and disability and care home staff and residents during an outbreak and for care home residents upon admission.
Unpaid carers and those visiting individuals in their own homes or in care homes do not need to regularly test, although they should continue to practice caution. Free tests are available for a small group of visitors providing personal care to loved ones in a care home to help prevent transmission and infection in high-risk communal settings.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact on (a) GP and (b) NHS capacity of the end of provision of free covid-19 lateral flow tests on 1 April 2022; and if he will make an assessment of...
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact on (a) GP and (b) NHS capacity of the end of provision of free covid-19 lateral flow tests on 1 April 2022; and if he will make an assessment of...
We are unable to provide the information requested on specific assessments as this relates to the development of Government policy. However, we continue with the National Health Service to assess the impact of the end of free universal testing on primary, community and acute healthcare settings. From 1 April 2022, our testing strategy is focussed on protecting the most vulnerable population groups and settings, continuing surveillance to identify variants of concern and maintaining the ability to respond to potential new variants. We will continue to provide some asymptomatic testing in NHS services during periods of higher prevalence, including for staff and patients.
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the impact of recently revised infection prevention and control guidance on the levels of protection against covid-19 for healthcare workers.
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the impact of recently revised infection prevention and control guidance on the levels of protection against covid-19 for healthcare workers.
The UK Health Security Agency and NHS England and NHS Improvement continuously monitor COVID-19 infection rates amongst healthcare workers in England and update guidance based on the scientific evidence. The impact of the latest revised infection prevention and control guidance, which was published on 14 April, is due to be discussed by the UK IPC Cell in May.